Auxly Cannabis Group Inc.

TSX:XLY.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.53 +0.00%

+$0.00 today

Market cap
$364.42M
Beta
1.16
P/E (TTM)
7.3
EPS (TTM)
$0.02
52W Low $0.08High $0.19

Volume 0.13M

Average 0.71M

XLY.TO Interest Expense

Cost of servicing the company's debt during the period.

Auxly Cannabis Group Inc.TSX: XLY.TO

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of CA$1.09M fell 49.1% year over year, behind the -45.7% change in trailing-twelve-month interest expense. Sequentially, it rose 20.7% from the prior quarter. Over 3 fiscal years it compounded at -33.5% a year.

Context

  • Interest expense amounted to 4.2% of revenue in FY2025, down 7.6 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -49.1% toward the trailing-twelve-month pace of -45.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$1.09M+20.7% QoQ
Last fiscal yearDec 2025
CA$6.34M-56.1% YoY
LTMMar 2026
CA$5.29M-45.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.1%——
1 year-56.1%——
3-year CAGR-33.5%——
5-year CAGR——
10-year CAGR——

Interest Expense history

CAD · from the income statement

Latest · FY2025
6.34M CAD
Year-over-year change
-56.1%
4-year CAGR
-22.6%

Interest Expense vs competitors

How XLY.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.7% is the lowest of 3, against a peer median of -30.1%.
  • Interest expense amounts to 3.3% of revenue for XLY.TO, versus a peer median of 6.2%.
XLY.TO Competitors
Interest Expense for XLY.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRRX.TOCareRx CorporationLTM Mar 2026CA$6.61M CAD-22.2%-23.4%1.8%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$5.88M USD-38.0%-0.5%10.5%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$5.29M CAD-45.7%-33.5%3.3%
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$0 CAD———
Peer median (excluding XLY.TO) —-30.1%-11.9%6.2%

Competitors are the stored peer set for XLY.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue83.83M94.47M101.08M122.33M151.48M
Cost of Revenue64.54M77.96M79.8M62.4M64.74M
Gross Profit19.29M16.51M21.28M59.93M86.74M
Gross Margin23.0%17.5%21.1%49.0%57.3%
Research & Development298K292K497K00
Selling, General & Admin45.42M50.38M40.28M40.73M49.07M
Operating Expenses58.23M65.49M47.23M45.22M54.07M
Depreciation & Amortization14.27M20.18M11.21M10.28M11.45M
EBITDA(18.3M)(94.79M)(10.89M)24.38M50.31M
EBITDA Margin-21.8%-100.3%-10.8%19.9%33.2%
Operating Income(38.94M)(48.98M)(25.95M)14.71M32.67M
Operating Margin-46.4%-51.8%-25.7%12.0%21.6%
Interest Income1.59M337K32K240K130K
Interest Expense17.67M21.58M25.65M14.46M6.34M
Other Income / Expenses(11.3M)(87.58M)(21.8M)(15.07M)(155K)
Income Before Tax(50.24M)(136.56M)(47.75M)(356K)32.52M
Pre-Tax Margin-59.9%-144.5%-47.2%-0.3%21.5%
Income Tax Expense(4.33M)(6.26M)(3.24M)15.99M(9.34M)
Net Income(33.74M)(130.29M)(44.51M)(16.35M)41.86M
Net Margin-40.2%-137.9%-44.0%-13.4%27.6%
EPS (Basic)(0.06)(0.15)(0.04)(0.01)0.03
EPS (Diluted)(0.06)(0.15)(0.04)(0.01)0.03
Weighted Avg Shares783.38M889.87M990.99M1.2B1.33B
Weighted Avg Shares (Diluted)783.38M889.87M990.99M1.2B1.59B

Auxly Cannabis Group Inc.

TSX:XLY.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.